Bictegravir/Emtricitabine/Tenofovir Alafenamide
- TRADE NAME: Biktarvy (Gilead)
- INDICATIONS: HIV-1 infection
- CLASS: Antiretroviral, Hepatitis B virus necleoside analog reverse transcriptase inhibitor (tenofovir alafenamide), Integrase strand transfer inhibitor (bictegravir), Nucleoside analog reverse transcriptase inhibitor (emtricitabine)
- HALF-LIFE: 17 hours (bictegravir); 10 hours (emtricitabine); <1 hour (tenofovir alafenamide)
FDA APPROVAL DATE: 02/07/2018
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Carbamazepine, Dofetilide, Metformin, Other antiretroviral drugs, Oxcarbazepine, Phenobarbital, Phenytoin, Rifabutin, Rifampin, Rifapentine, St John's Wort
PREGNANCY CATEGORY: N/A
Insufficient evidence to inform drug-associated risk
POST-TREATMENT ACUTE EXACERBATION OF HEPATITIS B
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
SKIN.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric